← All trials
NCT04752215
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 12, 2021
- Primary completion
- Feb 13, 2023
- Completion date
- Dec 15, 2024
- First posted
- Feb 12, 2021
- Last posted
- Dec 1, 2021
- Enrollment
- 120
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Boehringer IngelheimLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.